Authors

Latest:

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Drs Danilov and O'Brien discuss updates with acalabrutinib, zanubrutinib, and pirtobrutinib in CLL that were presented at the 2024 ASH Annual Meeting.

Susan M. OBrien, MD The University of California, Irvine Medical Center

Susan Moore, RN, MSN

Latest:

Susan Moore on Oral Oncolytic Patient Education

Susan Moore on the Importance of Oral Oncolytic Patient Education

Susan Moran, MD

Latest:

Effective Management and Prevention of Neratinib-Induced Diarrhea

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Susan N. Chi, MD

Latest:

Dr. Chi on Response to Tazemetostat in Children With INI1-Negative Tumors

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses response to tazemetostat in children with INI1-negative tumors.

Susan Oâ€™Brien, MD

Latest:

Dr. Susan O'Brien on Next-Generation Small Molecules in CLL

Susan OÃ¢â‚¬â„¢Brien, MD, Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses upcoming agents in chronic lymphocytic leukemia (CLL).

Susan Peck, PhD

Latest:

Putting Key Developments in Two Tumor Types in Focus

As the molecular understanding of breast cancer continues to evolve, the search for treatment targets based upon tumor subtypes and gene expression patterns is intensifying.

Susan R. Peck, PhD

Latest:

BATTLE-2: Next-Generation of Biomarker-Driven Trials

While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.

Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center

Latest:

Dr. Slovin on Selecting Among Available Treatment Options in mCSPC

Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.

Susan Sprague Yeske

Latest:

Oncology Nutritionists: Should cancer care teams include dietary experts?

Early screening and comprehensive assessment of risk for malnutrition is increasingly recognized as imperative in the development of standards of quality of care in oncology practices.

Susana Campos, MD, MPH

Latest:

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

Dr Campos discusses clinical implications from the gynecologic cancer cohorts of DESTINY-PanTumor02 and considerations for managing adverse effects in patients receiving T-DXd.

Susana M. Campos, MD

Latest:

Dr. Campos on Next Steps With PARP Inhibitors in Ovarian Cancer

Susana M. Campos, MD, gynecologic oncologist, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses next steps with PARP inhibitors in ovarian cancer.

Susana M. Campos, MD, MPH

Latest:

Key Takeaways and Closing Thoughts on ADCs

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Susanna Ulahannan, MD

Latest:

Dr. Ulahannan on the PRODIGE 35 Trial in Pancreatic Cancer

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the phase II PRODIGE 35/PANOPTIMOX trial in pancreatic cancer.

Susanne Osanto, MD, PhD, Leiden University Medical Center

Suzanne A. W. Fuqua, PhD

Latest:

Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.

Suzanne Beauchene, BSN, RN

Latest:

Suzanne Beauchene on the Provenge Treatment Process

Suzanne Beauchene from Seattle Cancer Care Alliance Discusses the Provenge Treatment Process from Start to Finish

Suzanne George, MD

Suzanne George, MD, is chief of the Division of Sarcoma and a senior physician at Dana-Farber Cancer Institute; as well as an associate professor of medicine at Harvard Medical School

Latest:

Dr George on the Clinical Relevance of Targetable Mutations in GIST

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

Suzanne L. Topalian, MD

Latest:

Dr. Topalian on the Immunosuppressive Tumor Microenvironment of Nasopharyngeal Cancer

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery and Oncology, Johns Hopkins Medicine, discusses the immunosuppressive microenvironment of nasopharyngeal cancer.

Swapna Goday, MD, MPH

Latest:

Using Smartphones to Access Medical Reference Information

Smartphones are becoming the most transformational IT solution to ever impact healthcare.